Trevi launches Phase 2b trial of Haduvio for chronic cough

Trevi launches Phase 2b trial of Haduvio for chronic cough

Trevi Therapeutics has launched a Phase 2b clinical trial testing therapeutic candidate Haduvio (nalbuphine extended-release tablets) for the treatment of chronic cough in people with idiopathic pulmonary fibrosis (IPF). The Phase 2b trial, CORAL (NCT05964335), plans to enroll about 160 adults with IPF and chronic cough. No…

Immune NK T-cells may be therapeutic target for IPF

Certain immune cells called natural killer (NK) T-cells are present at higher numbers in the lungs of people with idiopathic pulmonary fibrosis (IPF) than in the lungs of healthy people, according to data announced by GRI Bio. Also, the more NK T-cells, the greater the number of macrophages,…

First patient enrolled in TETON PPF study of nebulized Tyvaso

The first patient has been enrolled in a Phase 3 clinical trial of nebulized Tyvaso (treprostinil) inhalation solution for treating progressive pulmonary fibrosis (PPF), according to United Therapeutics, the therapy’s developer. Called TETON PPF (NCT05943535), the study will evaluate how safe Tyvaso is versus a placebo…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums